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Abstract A universal and robust analytical method for the
determination of Δ9-tetrahydrocannabinol (THC) and two
of its metabolites Δ9-(11-OH)-tetrahydrocannabinol (11-
OH-THC) and 11-nor-Δ9-carboxy-tetrahydrocannabinol
(THC-COOH) in human whole blood was developed and
validated for use in forensic toxicology. Protein precipita-
tion, integrated solid phase extraction and on-line enrich-
ment followed by high-performance liquid chromatography
separation and detection with a triple quadrupole mass
spectrometer were combined. The linear ranges used for the
three cannabinoids were from 0.5 to 20 ng/mL for THC and
11-OH-THC and from 2.5 to 100 ng/mL for THC-COOH,
therefore covering the requirements for forensic use.
Correlation coefficients of 0.9980 or better were achieved
for all three analytes. No relevant hydrolysis was observed
for THC-COOH glucuronide with this procedure — in
contrast to our previous GC-MS procedure, which obvi-
ously lead to an artificial increase of the THC-COOH
concentration due to the hydrolysis of the glucuronide-
conjugate occurring at high pH during the phase-transfer
catalyzed methylation step.
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Introduction
Driving under the influence of drugs is considered a serious
offense in many countries [1–8]. With a confirmed drug
level concentration either in whole blood or serum, drivers
will face a revocation of their driving license from one to
several months depending on the legal decisions. The
sentences differ from case to case depending on drug
concentration, consumption of one or several drugs or
combination with alcohol consumption. Accurate determi-
nation of the drug concentration is therefore a key factor
within the legal action.
In our laboratory, cannabis is the most frequently
encountered illicit drug with increasing number of cases
every year. In the past years, the control activity of police
and the number of positive tests for cannabis during traffic
controls or traffic accidents have increased. Switzerland,
among various other countries, has defined a threshold
value for Δ9-tetrahydrocannabinol (THC) concentration in
venous blood of suspected drivers. The current threshold
value (1.5 ng/mL of THC in whole blood) was introduced
by a federal court decision in 2005. Whenever the police
finds positive test results, during traffic controls or traffic
accidents, which could indicate earlier consumption of
cannabis, e.g., by urine or saliva drug test, the analysis of
THC and its two main metabolites in blood is required by
an analytical chromatographic technique such as GC or
HPLC. The capacity of our existing and validated method
based on GC-MS has been exceeded quite rapidly due to
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the time consuming sample preparation and relatively long
run time per injection (27 min in total) and the frequent
preventative cleaning of the GC-MS instrumentation. In
addition, it was not possible to measure several conse-
cutive series of samples without user intervention. Taking
this into consideration, a more automated and robust
method for the existing GC-MS analysis was needed
which could be in operation during days or even weeks
without maintenance.
Methods based on HPLC combined with triple
quadrupole mass spectrometry offer several advantages
over GC-MS methods: sample preparation is straight
forward, overall analysis times are generally shorter and
robustness increases when changing from GC to HPLC
separation since the HPLC injector port is less prone to
accumulating interferences. In addition, the lipophilic
portion of the cannabis extracts tends to remain on the
GC column.
THC is just one of more than 60 cannabinoid ingredients
found in hemp (Cannabis sativa). As a major difference to
most other illicit drugs, cannabinoids do not contain
nitrogen and therefore exhibit a lower ionization efficiency
during the electrospray ionization. THC and its two major
metabolites Δ9-(11-OH)-tetrahydrocannabinol (11-OH-
THC) and 11-nor-Δ9-carboxy-tetrahydrocannabinol
(THC-COOH), are as well lipophilic and polar. In recent
years, several scientific papers have been published [ref. 9–
31] on the determination and quantification of cannabinoids
in biological samples.
Experimental
Chemicals
Δ9-tetrahydocannabinol (THC), 11-OH-THC, 11-nor-Δ9-
carboxy-tetrahydrocannabinol and their tri-deuterated
internal standards [2H3]-Δ9-tetrahydocannabinol (d3-THC),
[2H3]-Δ9-(11-OH)-tetrahydrocannabinol (d3-11-OH-THC)
and [2H3]-11-nor-Δ9-carboxy-tetrahydrocannabinol (d3-
THC-COOH) were purchased from Cerilliant (Austin,
TX, USA). Acetonitrile supra gradient grade was
obtained from Biosolve (Chemie Brunschwig, Basel,
Switzerland) and HPLC-grade water was produced in-
house with a Milli-Q water system from Millipore
(Billerica, USA). Formic acid (puriss p.a., 98%) and
methanol (spectrophotometric grade, ≥99%) were pur-
chased from Fluka Sigma Aldrich (Buchs, Switzerland).
Precision pipettes from Socorex Isba S.A. (Lausanne,
Switzerland), Gilson (Mettmenstetten, Switzerland) and
Vaudaux-Eppendorf (Basel, Switzerland) were used for
handling of all solutions and all samples.
Preparation of calibration and quality control samples
The working solutions for spiking of calibration and quality
control samples were prepared in pure methanol in glass
screw cap vials by using two different diluting cascades
(one for calibration and one for quality control samples)
starting from two different 1.0 mg/mL stock solutions
(prepared from different lots) with working solutions
ranging from 10 μg/mL down to 0.025 μg/mL. Calibration
samples were spiked at concentration levels of 0.5, 1.0, 1.5,
2.0, 5.0, and 10 and 20 ng/mL for THC and 11-OH-THC
and 2.5, 5.0, 7.5, 10, 25, 50, and 100 ng/mL for THC-
COOH. Blank blood was obtained from the blood donor
center of Bern and the blood was tested before it was used.
Calibration and quality control samples were prepared
freshly for each sequence. The stability of working
solutions was tested while stored at 6°C and was found to
be stable for at least 6 months.
Sample preparation
For each sample (calibration, quality control, and
unknown), 200 μL of whole blood were transferred into a
2.0 mL microtube (Sarstedt, Nümbrecht, Germany) and
spiked with 20 μL of internal standard solution, containing
2 ng of d3-THC and d3-11-OH-THC and 10 ng d3-THC-
COOH. For blank samples, 20 μL of methanol was added
instead.
Proteins were precipitated by adding 600 μL of
acetonitrile into the microtubes, then mixed by vortexing
for 5 min and finally centrifugated for 10 min at
13,000 rpm. The supernatant solutions were transferred
into glass vials (1.5 mL, Infochroma, Zug, Switzerland) and
evaporated at 50°C under a gentle stream of nitrogen.
Eventually, 200 μL of an acetonitrile/water/formic acid (60/
40/0.1; v/v/v) solution were added to each vial and shaken
for 1 min until dissolution of the residues was complete.
Fifty microliters of the reconstituted solution were injected
into the HPLC-MS/MS system. The concentration step was
necessary due to the limited sensitivity of the mass
spectrometer.
Chromatographic system
The prepared samples were injected onto a SPE column
(Mercury Synergy, Polar RP, 20×2.0 mm, Phenomenex,
Torrance CA, USA) with a diluting flow during the
injection step in order to retain all three analytes on the
trapping column. From a 100 μL autosampler loop, the
samples were loaded with a 0.5 mL/min flow (acetonitrile/
water/formic acid, 30/70/0.01; v/v/v) onto the trapping
column and diluted by a T-union with an aqueous flow of
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0.3 mL/min (water + 0.1% formic acid) in order to
maximize the loading and trapping step. Pump 5 was used
for the dilution of the injection solution. The extraction and
transfer over to the analytical column was performed using
a linear gradient of aqueous formic acid as mobile phase A
(water + 0.1% formic acid) and acetonitrile containing
formic acid as mobile phase B (acetonitrile + 0.1% formic
acid). The autosampler compartment was set to a temper-
ature of 6°C.
Liquid chromatography equipment consisted of two
solvent racks SRD-3200, two binary HPLC pumps HPG-
3200A, an isocratic pump ISO-3000-SD, a heated column
compartment TC-3100 with a built-in 10-port switching
valve and an autosampler WPS-3200 TSL (Dionex, Olten
SO, Switzerland). An additional column heater (Croco-Cil
from Cluzeau Info Labo C.I.L., Courbevoi, France) was
used to heat the analytical column. For the analytical
separation, a 100×2.0 mm column with 3 μm particles
(Luna C8 (II), Phenomenex, Torrance CA, USA) was used.
All HPLC components, the valves and the mass spectro-
meter were controlled by MDS Sciex Analyst software.
In Table 1, the gradient program for the two high
pressure pumps and the diluting pump is illustrated. Both
gradients were optimized for best sensitivity, to reduce
matrix effects and to separate all interferences from the
analyte peaks. An important point was the organic
cleaning of the SPE column with mobile phase B from
13 to 14 min which prevents any accumulation inside the
SPE column.
Mass spectrometry
A triple-stage quadrupole mass spectrometer with linear
ion trap capability (3200 QTrap, Analyst software
(version 1.4.1), Applied Biosystems/MDS Sciex, Rotkreuz,
Switzerland) was used in selective reaction monitoring (SRM)
scan mode for the mass spectrometric detection. Electrospray
ionization was performed in positive ion mode for all
three analytes and the following instrument parameters
for ionization were used: ion source voltage, 5000 V;
curtain gas, 25; gas 1, 60; and gas 2, 40 (arbitrary units
for the gas settings).
Table 1 Gradient program for all HPLC pumps and events for the switching valve
Time (min) Pumps 1 and 2 (AC: analytical column) Pumps 3 and 4, pump 5 (SPE: trapping column)
Mobile phase B Flow Comments Mobile phase B Flow Flow Pump 5 Switching valve
% μl/min % μl/min μl/min
0.00 30 350 Start MS, start pumps 50 500 300 SPE → waste
AC → MS
(loading)
1.00 30 Start gradient 50 500 300 SPE → AC → MS
(eluting)
1.20 ↓ 50 500 300
1.30 50 20 20
3.00 60
↓
8.00 85
9.20 85
9.21 97.5
12.60 97.5
12.70 97.5 100 1000
13.00 97.5 350 100 1000 SPE → waste
AC → MS
(Re-equilibrating)
13.01 30 350 100 1000
14.00 100 1000
14.01 50 1000
14.50 50 1000
14.60 50 500
15.00 End of program 50 500 End of program
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The positioning of the spray needle was optimized to
obtain best signal to noise ratios for the lowest calibration
level for THC. Each of the three analytes were measured
with two SRM transitions, whereas for the internal stand-
ards only one transition was used. For the analyte
transitions a dwell time of 50 ms was used while for the
three internal standard transitions 25 ms dwell time was
applied (resulting in approximately 13 data points per
peak). The difference in dwell time was chosen in order to
have better ion statistics around the LLOQ. In Table 2, the
detailed descriptions of the tuning parameters for each
compound are shown. All calculations were performed on
analyte to internal standard ratio using the MDS Sciex
Analyst software. The second transition was used as a
qualifier trace in order to confirm presence or absence of
the analytes (see Electronic Supplementary Material). All
SRM transitions were automatically optimized via software
using the quantitative optimization algorithm of the MDS
Sciex Analyst software. Ion source parameters were
manually adjusted with loop injections by a standard
solution containing all three analytes.
System suitability test
In order to observe run-to-run and day-to-day performance
variation a system suitability test was carried out before
each sequence. The goal of this system suitability test was
to ensure the correct functions of the complete HPLC-MS/
MS system, to build up a history of the instrument
performance and to monitor the role of all consumables
such as solvents, buffers, vials and the used instrumenta-
tion. For this purpose, a standard solution (20 μL of a
methanolic solution containing 10 ng/mL THC, 20 ng/mL
11-OH-THC and 50 ng/mL THC-COOH) was transferred
into a sample vial, then the solvent was evaporated and
finally the residue was dissolved in 200 μL of a solution
containing acetonitrile/water/formic acid (60/40/0.1; v/v/v).
All compounds had to be automatically recognized by the
MDS Sciex Analyst software and chromatographic peak
shapes, retention times, interferences and signal to noise
ratios had to be within a range of predefined values and the
Analyst quantification method values for smoothing and
bunching factors (retention time for all three analytes
(THC: 8.78 min, 11-OH-THC: 6.58 min, THC-COOH:
6.61 min), retention time window of 30 s, smoothing width
three and peak-splitting factor one for all three compounds).
Validation
A validation plan was set up according to ISO 17025 and
parts of the FDA guidelines for bioanalytical method
validation were incorporated [31–33].
Selectivity, linearity, post-preparative stability, freeze/
thaw stability, precision, limits of detection and quantifica-
tion and the robustness of the analytical method were
determined. The LLOQ was chosen in order to meet the
current threshold value (1.5 ng/mL of THC in whole blood)
with a reasonable safety margin and a linear range which
would cover the expected concentration range and the
LLOQs were back calculated by the DIN 32645 procedure
as well. Existing results obtained by GC-MS were
compared to the newly acquired HPLC-MS/MS data.
Results and discussion
Method validation
Selectivity was measured on the analyte-free solvents (for
the system suitability test), on analyte-free matrix from six
different subjects from the blood donor service and from
authentic investigations. These samples were tested for the
absence of all three analytes. Used as blank samples or,
after addition of internal standard, QC zero samples, no
traces of analytes or significant interferences could be
detected (see Electronic Supplementary Material).
The lowest calibration sample for THC and 11-OH-THC
(0.5 ng/mL) as well as for THC-COOH (2.5 ng/mL) achieved
acceptable signal to noise ratios during integration (s/n>60
for THC and THC-COOH, s/n>15 for 11-OH-THC). 11-
OH-THC showed the lowest sensitivity of all three analytes,
but the quantification was still precise and could be
quantified without any problems. Typical chromatograms
for the limits of quantification are summarized in Fig. 1.
Linear ranges from 0.5 to 20 ng/mL for THC and 11-
OH-THC and from 2.5 to 100 ng/mL for THC-COOH were
Compound Quantifier Qualifier Orifice CE
THC 315.2→193.2 315.2→123.2 41 29/43
11-OH-THC 331.2→313.2 331.2→193.2 51 17/37
THC-COOH 345.2→327.3 345.2→299.2 56 19/23
d3-THC 318.3→196.3 41 29
d3-11-OH-THC 334.3→316.3 51 17
d3-THC-COOH 348.2→330.3 56 19
Table 2 SRM transitions used
for compound quantification and
confirmation and optimized
parameters for each SRM tran-
sition (CE: collision energy)
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used in order to achieve correlation coefficients (r) better
than 0.9980. The relative narrow ranges were selected,
since it was essential to have enough reference points
around the legal threshold value whereas measured con-
centrations above the highest calibration point are always
considered as a positive test result and do not need further
verification or re-measurement after dilution.
Each validation sequence contained 14 calibration
samples at seven different levels. A first order calibration
(y=a × x+b) without weighting factor was applied. During
the validation runs from seven calibration samples, corre-
lation coefficients were at least 0.9980 for THC, 11-OH-
THC and THC-COOH, respectively.
Accuracy and imprecision of the method (during three
validation runs prepared on three different days) were tested
with four QC levels and the commercially available
Medichem drug control standard as an external QC
containing 1.4 ng/mL THC, 1.6 ng/mL 11-OH-THC and
32.3 ng/mL THC-COOH. Six replicates of every QC level
were measured and the following results were achieved (for
three runs): inter-assay accuracy was equal or better than
88.1% for THC, 99.7% for 11-OH-THC and 92.8% for
THC-COOH; inter-assay imprecision was equal or better
than 9.8% CV for THC, 10.8% CV for 11-OH-THC and
5.4% CV for THC-COOH.
Inter-personnel comparison was performed on two runs
with two laboratory technicians and the coefficients of
variation were equal or below 7.45% CV for THC, 6.52%
CV for 11-OH-THC and 3.60% CV for THC-COOH.
In addition, the Valistat software (Arvecon GmbH,
version 2.0) was used for assessment of the detection limits
and quantification limits according to the DIN 32645
standard procedure (area ratio was used for the calcula-
tions). The following values were obtained for the detection
limits: 0.18 ng/mL for THC, 0.18 ng/mL of 11-OH-THC
and 0.85 ng/mL for THC-COOH. For the quantification
limits, 0.44 ng/mL for THC, 0.45 ng/mL for 11-OH-THC,
and 2.0 ng/mL for THC-COOH were obtained.
Short-term stability was measured based on three
replicates of two calibration curves. The first calibration
curve was prepared and analyzed directly after spiking
while the second calibration curve was prepared and
analyzed after 6 h at room temperature. The lowest
calibration point showed a decrease of 11% for THC,
whereas for all other calibration points the relative devia-
tions were smaller than 5% compared to their first values.
Fig. 1 Typical chromatogram for the lowest calibration level of THC, 11-OH-THC and THC-COOH (0.50 ng/mL THC, 0.5 ng/mL 11-OH-THC
and 2.5 ng/mL THC-COOH in whole blood)
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Re-injection (autosampler) stability was determined with
one sequence of authentic samples and six replicates of the
Medichem control samples. These samples were analyzed
immediately after sample preparation and then kept at 6°C
for 6 days. After this period, the run was re-injected and the
relative deviation for every authentic sample and for each
Medichem control sample was below 15% compared to the
first measurement.
Freeze/thaw stability was measured with sets of the
lowest and highest calibration sample and the Medichem
control samples. Each of the three cycles consisted of 4 h
at room temperature at about 20 °C (thaw) and 20 h at
about −20 °C (freeze). THC showed a decrease of 15.1% for
the lowest calibration point after three cycles, whereas all
other samples showed less than 15% deviation compared to
their initial values.
Overall recoveries (including on-line SPE and sample
preparation) were measured in whole blood samples against
pure methanolic solutions and showed average recoveries
of 78% for THC, 46% for 11-OH-THC and 52% for THC-
COOH, 74% for d3-THC, 47% d3-11-OH-THC and 45%
for d3-THC-COOH. Since the sensitivity was sufficient
with the current method, no further efforts were made in
order to improve the recoveries of the two metabolites.
Matrix effects on all three compounds were tested by
infusing a solution containing 10 ng/mL THC, 11-OH-THC
and THC-COOH via a T-union and injection of prepared
blank blood samples from six different subjects. No signifi-
cant changes of the ion intensities were observed for all three
compounds during the analytes’ retention times.
Possible carry over was investigated on a sequence with
two injections of the highest calibration level followed by
three injections of blank samples. No traces of the three
compounds were found during these injections (see
Electronic Supplementary Material).
Ion ratios between quantifier and qualifier were identi-
fied on three validation runs and then implemented for the
routine work. For THC, a mean ratio between quantifier
and qualifier of 1.67, for 11-OH-THC a mean ratio of 6.0
and for THC-COOH a mean ratio of 1.75 was determined.
During the validation, the largest deviation of a single value
observed was 18.1% for THC, −20.1% for 11-OH-THC and
5.6% THC-COOH.
The specificity of the internal standard ion traces was
tested on six different positive patient samples where
THC and both metabolites had previously been mea-
sured. For all of these six samples, THC was higher than
32 ng/mL and THC-COOH higher than 58 ng/mL. These
samples were prepared and measured as blank samples
without adding ISTD. No interferences for the internal
standards’ ion traces could be observed compared to the
intensities of the internal standards during regular
measurement (see Electronic Supplementary Material).
For synthetic cannabinoids a mixture of JWH-015,
JWH-018, JWH-073, JWH-081, JWH-200, JWH-250,
WIN 55,212-2, JWH-019 and JWH-020 was spiked into
blank blood to a level of 100 ng/mL. Two different
samples (blank blood from two different subjects) were
measured as blank samples and no interferences with the
internal standard ion traces were found (see Electronic
Supplementary Material).
For samples above the calibration range the dilution ability
was tested with six samples spiked to 100 ng/mL for THC and
11-OH-THC and 500 ng/mL for THC-COOH. After a tenfold
dilution with blank blood, the results showed a maximum
deviation of 8.1% to their nominal value.
Routine data
During routine analysis six externally purchased quality
control samples (from Medichem) are measured within each
sequence for accuracy and precision verification. Each run
contains typically between 20 to 40 unknown samples which
are always measured in duplicate. In 50 runs measured in the
last few months (corresponds to about 300 externally
purchased quality control samples), the accuracy of each
single value for THCwas within 15% deviation except for one
(reference value of 2.62 ng/mL for the Medichem reference;
lowest value measured during the 50 runs: 2.24 ng/mL,
highest value measured: 3.08 ng/mL). For 11-OH-THC and
for THC-COOH, very few values were outside 15% deviation
and no single run during these 50 sequences failed, proving
the robustness of the LC-MS/MS method.
Ion ratios between quantifier and qualifier are used as quality
control criteria for unequivocal identification of the analyte
during routine analysis. Single values with more than 30%
deviation from the mean value are investigated or re-analyzed.
The intensities of the three internal standards are monitored
during data processing for possible sample preparation errors,
but are generally within ±15% deviation from the mean value
(see Electronic supplementary material).
Method comparison
The previously used GC-MS method was based on off-line
SPE of 1.0 mL of whole blood combined with methylation and
a twofold liquid–liquid extraction with octane and reconstitution
in ethylacetate (LLOQswere 1.5 ng/mL for THC, 2.0 ng/mL for
11-OH-THC, and 8.0 ng/mL of THC-COOH).
LC-MS/MS reveals two trends: the measured concen-
trations of THC are slightly higher when measured with the
LC-MS/MS, in average about 16.1% compared to the GC-
MS method as illustrated in Table 3. Still the results provide
good agreement for both measurement techniques for the
determination of the THC concentration which is used
during the legal process.
14 S. König et al.
For the two metabolites though, lower concentrations
were measured when using the LC-MS/MS method
compared to the GC-MS method (in average 19.8% for
the 11-OH-THC and 62.1% for the THC-COOH). The
amount of the glucuronide of the THC-COOH (another
major metabolite) present in authentic samples does not
contribute to the THC-COOH concentration when using the
LC-MS/MS method (this has been tested by using THC-
COOH glucuronide which is commercially available from
Cerilliant; when samples spiked with THC-COOH glucu-
ronide are measured by the LC-MS/MS method no peak
appears for the THC-COOH; data not shown).
However, during the sample preparation for the GC-MS
method which includes an extraction by SPE with high
recovery of THC-COOH glucuronide in the extract, and a
subsequent phase-transfer catalyzed methylation step at a high
pH value with tetramethylammonium hydroxide solution, a
significant portion of the THC-COOH glucuronide present in
authentic blood samples was hydrolyzed and therefore
contributed to the measured THC-COOH concentration.
Several sources reported comparable results for the hydrolysis
of the THC-COOH glucuronide [34–38]. In addition, with
LC-MS/MS the glucuronide of THC-COOH is baseline
separated (see Electronic Supplementary Material) from
THC-COOH and therefore does not contribute to the
unconjugated THC-COOH value due to possible in-source
fragmentation during the ionization process.
For the differences of the measured 11-OH-THC con-
centrations, a similar mechanism can be postulated, but the
details were not investigated during this study.
Conclusions
With the introduction of threshold values for commonly
abused drugs, Swiss traffic laws are bridging the gap
between offenses from driving under the influence of
alcohol or drugs. Currently, state courts and traffic admin-
Table 3 Measured concentrations of THC, 11-OH-THC and THC-COOH from 25 authentic DUID cases measured by GC-MS and LC-MS/MS
(blq: below limit of quantification) and their relative deviation
Case
number
THC 11-OH-THC THC-COOH
GC-MS [ng/mL] LC-MS/MS
[ng/mL]
Relative
deviation [%]
GC-MS
[ng/mL]
LC-MS/MS
[ng/mL]
Relative
deviation [%]
GC-MS
[ng/mL]
LC-MS/MS
[ng/mL]
Relative
deviation [%]
1 9.2 11 19.6 3.2 2.7 −15.6 86 42 −51.2
2 3.8 4.3 13.2 blq 1.2 − 32 10 −68.8
2 7.4 8.9 20.3 8.6 7.2 −16.3 422 172 −59.2
4 blq blq − blq blq − blq blq −
5 3.1 3.6 16.1 blq 1.2 − 121 39 −67.8
6 blq 1.3 − blq 0.7 − 57 16 −71.9
7 blq 0.6 − blq blq − 5.6 2.7 −51.8
8 7.5 8.1 8.0 3.8 3.3 −13.2 85 37 −56.5
9 1.6 1.7 6.3 blq blq − 17 4.3 −74.7
10 1.2 1.3 8.3 blq 0.6 − 44 19 −56.8
11 1.4 1.7 21.4 blq 0.6 − blq 4.2 −
12 3.6 4.3 19.4 2.0 1.4 −30.0 105 40 −61.9
13 17 20 17.6 4.5 3.4 −24.4 214 58 −72.9
14 blq blq − blq blq − 10 5.9 −41.0
15 blq blq − blq blq − blq 2.6 −
16 4.4 5.2 18.2 blq 1.3 − 71 23 −67.6
17 22 24 9.1 6.7 5.9 −11.9 463 148 −68.0
18 12 13 8.3 5.3 4.5 −15.1 127 66 −48.0
19 1.9 2.2 15.8 blq 0.6 − 33 15 −54.5
20 2.7 3.2 18.5 blq 0.6 − 35 8.9 −74.6
21 2.7 3.2 18.5 blq 0.9 − 95 31 −67.4
22 blq blq − blq blq − 22 7.4 −66.4
23 3.8 4.4 15.8 2.2 1.8 −18.2 74 30 −59.5
24 blq blq − blq blq − blq blq −
25 1.8 2.4 33.3 blq blq − 84 31 −63.1
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istrations are receiving blood alcohol results within 24 to
48 h after the samples have arrived in our laboratory. With
increasing numbers of cannabis samples to be analyzed,
authorities are urging to receive drug concentrations from
suspected drivers within a few days as well. With this paper
describing our current established method for the measure-
ment of THC, a first step into shorter turnaround time from
sample collection to reporting the results is made. This
study presents a robust method for the determination of
cannabinoids in whole blood based on on-line SPE,
combined with LC-MS/MS by column switching. The
LC-MS/MS method reduces the time needed for sample
preparation, sample consumption, measurement time and
cycles for preventive maintenance of the instrumentation
compared with our earlier GC-MS routine.
Column switching with on-line SPE/enrichment and
purification offers several advantages over direct injection
onto an analytical column: injection volumes can be
adjusted according to the sensitivity of the different mass
spectrometers, matrix effects are reduced due to the clean-
up step and an increase in robustness is observed as well.
The THC concentrations for authentic cases obtained by
GC-MS or by LC-MS/MS were consistent and for the two
metabolites the differences could be explained by artifact
formation due to the derivatization at basic pH for the GC-MS
technique. The current LC-MS/MS method, in routine use
since beginning of 2008, has been used to analyze thousands
of samples. Furthermore, our laboratory has successfully
participated in three European proficiency tests where the
results were within a few percent of the reference values.
Nevertheless, more automation and easier sample prep-
aration is needed in order to catch up with the increasing
demand for cannabis determinations. A critical review of
the currently used GC-MS methods is necessary as well,
since THC-COOH glucuronide hydrolysis needs to be
excluded or total THC-COOH should be determined after
mostly quantitative hydrolysis of the glucuronide-conjugate,
e.g., by enzymatic or chemical hydrolysis, to obtain repro-
ducible results in different laboratories.
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